Andre Chen

Dr. Andre Chen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2024 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ACAndre Chen
Andre Chen
ASAlexandre Ruggieri Serante
Alexandre Ruggieri Serante
AAAline Sgnolf Ayres
Aline Sgnolf Ayres
JTJuliana Ono Tonaki
Juliana Ono Tonaki
RMRaquel Andrade Moreno
Raquel Andrade Moreno
EWEduardo Weltman
Eduardo Weltman

1 January 2020 in Clinics
Verified
Journal Article
Open access
ACAndre Chen
Andre Chen
CMCamila Motta Venchiarutti Moniz
Camila Motta Venchiarutti Moniz
URUlysses Ribeiro-Júnior
Ulysses Ribeiro-Júnior
MEMaria Del Pilar Estevez-Diz
Maria Del Pilar Estevez-Diz
JSJoão Victor Salvajoli
João Victor Salvajoli
PHPaulo Marcelo Gehm Hoff
Paulo Marcelo Gehm Hoff

1 May 2018 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ACAndre Chen
Andre Chen
GMGeovanne Pedro Mauro
Geovanne Pedro Mauro
FGFlavia Gabrielli
Flavia Gabrielli
CCCristiane de Lacerda Gonçalves Chaves
Cristiane de Lacerda Gonçalves Chaves
ICIgor Castro
Igor Castro
HCHeloisa Andrade de Carvalho
Heloisa Andrade de Carvalho

22 April 2022 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ACAndre Chen
Andre Chen
CHCarlos Bo Chur Hong
Carlos Bo Chur Hong
DNDouglas Kenji Narazaki
Douglas Kenji Narazaki
VRVirginio Rubin
Virginio Rubin
ASAlexandre Ruggieri Serante
Alexandre Ruggieri Serante
WTWilliam Gemio Jacobsen Teixeira
William Gemio Jacobsen Teixeira

1 June 2023 in JCO Global Oncology
Verified
Journal Article
Open access
LFLeonardo Da Fonseca
Leonardo Da Fonseca
ACAndre Chen
Andre Chen
IOIrai S. de Oliveira
Irai S. de Oliveira
ACAline L. Chagas
Aline L. Chagas
JKJaime A.P. Kruger
Jaime A.P. Kruger
FCFlair J. Carrilho
Flair J. Carrilho
The incidence of hepatocellular carcinoma (HCC) is expected to increase in the coming years, and strategies to mitigate the burden of this disease are needed in different regions. Geographic variations in epidemiology and risk factors, such as viral hepatitis and metabolic disease, pose challenges in adopting programs for early detection programs and management of patients with HCC. Brazil, like other countries, has high economic and social inequality, with heterogeneous access to health care. Viral hepatitis is the main risk factor but there is growing awareness of fatty liver disease. Risk factor monitoring and screening programs are unmet priorities because patients are often diagnosed at later stages. Advances in the management of patients with HCC have been made in recent years, including new tools for selecting patients for liver transplantation, sophisticated surgical techniques, and new systemic agents. High-volume academic centers often achieve favorable results through the adoption and application of established treatments, but this is not a reality in most regions of Brazil, because of disparities in wealth and resources. As HCC management requires a coordinated and multidisciplinary team, the role of local referral centers in decentralizing access to treatments and promoting health education in different regions should be encouraged and supported.

14 April 2021 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Open access
PDF file
ACAndre Chen
Andre Chen
FPFabio Payão
Fabio Payão
ACAline Lopes Chagas
Aline Lopes Chagas
RARegiane Saraiva De Souza Melo Alencar
Regiane Saraiva De Souza Melo Alencar
CTClaudia Megumi Tani
Claudia Megumi Tani
FCFlair José Carrilho
Flair José Carrilho
BACKGROUND: The aim of the study was to evaluate the feasibility and safety of stereotactic body radiotherapy (SBRT) for the treatment of hepatocellular carcinoma in Brazil. SBRT is an evolving treatment in HCC patients not candidates to other local therapies. Its adoption in clinical practice has been heterogeneous, with lack of data on its generalizability in the Brazilian population. MATERIALS AND METHODS: We conducted a prospective pilot study involving HCC patients after failure or ineligibility for transarterial chemoembolization. Patients received SBRT 30 to 50 Gy in 5 fractions using an isotoxic prescription approach. This study is registered at clinicaltrials.gov NCT02221778. RESULTS: From Nov 2014 through Aug 2019, 26 patients received SBRT with 40 Gy median dose. Underlying liver disease was hepatitis C, hepatitis B and alcohol-related in, respectively, 50%, 23% and 19% of patients. Median lesion size was 3.8 cm (range, 1.5–10 cm), and 46% had multiple lesions. Thirty-two percent had tumor vascular thrombosis; median pretreatment alpha-fetoprotein (AFP) was 171.7 ng/mL (range, 4.2–5,494 ng/mL). 1y-local progression-free survival (PFS) was 86% (95% CI: 61% to 95%), with higher local control in doses ≥ 45Gy (p = 0.037; HR = 0.12). 1y-liver PFS, distant PFS and OS were, respectively, 52%, 77% and 79%. Objective response was seen in 89% of patients, with 3 months post-SBRT median AFP of 12 ng/mL (2.4–637 ng/mL). There were no grade 3 or 4 clinical toxicities. Grade 3 or 4 laboratory toxicities occurred in 27% of patients. CONCLUSION: SBRT is feasible and safe in patients unresponsive or ineligible for TACE in Brazil. Our study suggests doses > 45Gy yields better local control. BACKGROUND: The aim of the study was to evaluate the feasibility and safety of stereotactic body radiotherapy (SBRT) for the treatment of hepatocellular carcinoma in Brazil. SBRT is an evolving treatment in HCC patients not candidates to other local therapies. Its adoption in clinical practice has been heterogeneous, with lack of data on its generalizability in the Brazilian population. MATERIALS AND METHODS: We conducted a prospective pilot study involving HCC patients after failure or ineligibility for transarterial chemoembolization. Patients received SBRT 30 to 50 Gy in 5 fractions using an isotoxic prescription approach. This study is registered at clinicaltrials.gov NCT02221778. RESULTS: From Nov 2014 through Aug 2019, 26 patients received SBRT with 40 Gy median dose. Underlying liver disease was hepatitis C, hepatitis B and alcohol-related in, respectively, 50%, 23% and 19% of patients. Median lesion size was 3.8 cm (range, 1.5–10 cm), and 46% had multiple lesions. Thirty-two percent had tumor vascular thrombosis; median pretreatment alpha-fetoprotein (AFP) was 171.7 ng/mL (range, 4.2–5,494 ng/mL). 1y-local progression-free survival (PFS) was 86% (95% CI: 61% to 95%), with higher local control in doses ≥ 45Gy (p = 0.037; HR = 0.12). 1y-liver PFS, distant PFS and OS were, respectively, 52%, 77% and 79%. Objective response was seen in 89% of patients, with 3 months post-SBRT median AFP of 12 ng/mL (2.4–637 ng/mL). There were no grade 3 or 4 clinical toxicities. Grade 3 or 4 laboratory toxicities occurred in 27% of patients. CONCLUSION: SBRT is feasible and safe in patients unresponsive or ineligible for TACE in Brazil. Our study suggests doses > 45Gy yields better local control.